Future MDMA Treatment Following FDA's Rejection
from Cato Podcast
The FDA's rejection of MDMA as a treatment may well be a short-term setback for legally helping people with PTSD and other disorders. Mason Marks of Harvard Law School’s Petrie-Flom Center for Health Law Policy offers his assessment.
Embed this episode
No transcript yet.
Frequently asked questions
How long is this episode of Cato Podcast?
This episode is 24 minutes long.
When was this Cato Podcast episode published?
This episode was published on September 13, 2024.
Can I download this Cato Podcast episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.